Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Medical Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Revenue projections:

Revenue projections for BDX
Revenue projections for BDX

Revenues for BDX are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.942000
forwardPE 11.514566
debtToEquity 71.599000
earningsGrowth 0.000000
revenueGrowth 0.052000
grossMargins 0.470910
operatingMargins 0.147430
trailingEps 5.590000
forwardEps 13.416050

Becton, Dickinson and Company's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
With Becton, Dickinson and Company's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in Becton, Dickinson and Company's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for BDX
Price projections for BDX

BDX's price projections have gradually decreased, indicating a more conservative outlook from analysts. The repeated downward revisions suggest waning confidence in the company's ability to achieve its previous targets.

Insider Transactions:

Insider Transactions for BDX
Insider Transactions for BDX


There were 22 transactions selling BDX stock, with prevailing market price of 152.58819302645597.1 separate purchases of BDX stock were made, while market price was at 151.3364715576172 per share.BDX's current price levels have seen more sells, possibly signaling bearish sentiment. If this trend remains unchanged, the stock could experience further declines as more investors opt to sell rather than hold their positions.

Recommendation changes over time:

Recommendations trend for BDX
Recommendations trend for BDX


A recent buy bias from analysts toward Becton, Dickinson and Company may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that Becton, Dickinson and Company might be an appealing option for those looking to grow their wealth through stock market investments.